Patients' and physicians' perspectives on pharmacogenetic testing

被引:94
|
作者
Rogausch, A
Prause, D
Schallenberg, A
Brockmöller, J
Himmel, W
机构
[1] Univ Gottingen, Dept Gen Practice Family Med, D-37073 Gottingen, Germany
[2] Univ Gottingen, Dept Clin Pharmacol, D-37073 Gottingen, Germany
关键词
attitude of health personnel; delivery of healthcare; ethics; patient acceptance of healthcare; pharmacogenetics;
D O I
10.2217/14622416.7.1.49
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The integration of pharmacogenetic testing into routine care will, in part, depend upon the patients' and physicians' acceptance of these tests. Empirical data regarding patients' and physicians' views on pharmacogenetic testing are lacking. Objectives: To explore patients' and physicians' perspectives on the potential implications of pharmacogenetic testing, particularly focusing on asthma, and to analyze the possible determinants of their expectations, hopes and fears. Methods: We conducted telephone interviews with patients with asthma or chronic obstructive pulmonary disease taking part in a larger pharmacogenetic study, in addition to general practitioners (GPs) from a different region in Germany. A total of 328 patients and 378 GPs were invited to participate. Determinants of their attitudes toward pharmacogenetic testing were assessed using logistic regression analysis. Results: Informed consent to participate in this study was given by 196 patients (60%) and 106 GPs (28%). Most patients (96%) and physicians (52%) appreciated the availability of pharmacogenetic tests for a disease such as asthma. Approximately a third of the patients worried about potential unfavorable test results (35%) and violation of privacy (36%). Female patients were more likely to have a fearful attitude (odds ratio [OR]=2.85; 95% confidence interval [CI]=1.58-5.12). Younger patients were generally more likely to be hopeful about the usefulness of pharmacogenetic testing (OR=2.12; CI=1.01-4.46). The GPs' concerns were mainly related to the possibility that patients might either be put under pressure to be tested (72%) or be disadvantaged at private health insurance agencies (61%). The nature of the responsible institution, the clarity of the research aim and explicit informed consent from patients influenced a physicians' decision regarding whether to support a pharmacogenetic study. Conclusion: The concerns of patients and GPs differ somewhat with respect to negative psychosocial consequences, discrimination or violation of privacy. Development of information for physicians and patients would be helpful in preventing unrealistic fears or hopes.
引用
收藏
页码:49 / 59
页数:11
相关论文
共 50 条
  • [21] Cancer Patients' Preferences for Pharmacogenetic Testing (PGx)
    Cuffe, Sinead
    Hon, Henrique
    Qiu, Xin
    Tobros, Kimberly
    De Souza, Bradley
    McFarlane, Graham
    Wong, Chung-Kwun Amy
    Masroor, Sohaib
    Azad, Abdul Kalam
    Hasani, Ekta
    Rozanec, Natalie
    Leighl, Natasha
    Alibhai, Shabbir
    Xu, Wei
    Issa, Amalia M.
    Liu, Geoffrey
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 204 - 204
  • [22] Pharmacogenetic testing
    Debenham, P.
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2004, 56 : S99 - S99
  • [23] Physicians' Preparedness for Integration of Genomic and Pharmacogenetic Testing into Practice Within a Major Healthcare System
    Selkirk, Christina G.
    Weissman, Scott M.
    Anderson, Andy
    Hulick, Peter J.
    [J]. GENETIC TESTING AND MOLECULAR BIOMARKERS, 2013, 17 (03) : 219 - 225
  • [24] ATTITUDES ON WARFARIN PHARMACOGENETIC TESTING IN CHINESE PATIENTS AND PUBLIC
    Chan, Sze Ling
    Low, Joshua Jun Wen
    Chia, Kee Seng
    Wee, Hwee-Lin
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2014, 30 (01) : 113 - 120
  • [25] Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel
    Megan M. Donohue
    David L. Tirschwell
    [J]. Current Neurology and Neuroscience Reports, 2011, 11 : 52 - 60
  • [26] Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel
    Donohue, Megan M.
    Tirschwell, David L.
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2011, 11 (01) : 52 - 60
  • [27] Pharmacogenetic testing in the management of patients with prosthetic heart valves
    Gorbunova, E., V
    Ponasenko, A., V
    Barbarash, O. L.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 3393 - 3393
  • [28] ISSUES IN PHARMACOGENETIC TESTING
    Kennedy, James L.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S762 - S762
  • [29] Pharmacogenetic Testing and Opioids
    Collins, Tennille
    Nykamp, Diane
    [J]. US PHARMACIST, 2015, 40 (03) : 23 - 26
  • [30] Consent in Pharmacogenetic Testing
    Ando, Yuichi
    Terada, Tomohiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22)